IM Cannabis
IM Cannabis' revenue rose 1.3% to C$55 million in fiscal 2025. Its operating margin was −21.2%, down from −18.9% a year earlier. Free cash flow was C$5 million.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Income statement
IM Cannabis lost money in fiscal 2025: a net loss of C$11 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 17 | — | 2 | 1 | 3 |
| Debt incl. finance leases | 13 | 10 | 13 | 16 | 16 |
| Net debt (negative means net cash) | −4 | — | 11 | 15 | 14 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.1x | 0.4x | 0.9x | 3.1x | — |
| Interest coverage | −34.2x | −15.6x | −3.5x | −2.1x | −3.3x |
| Current ratio | 1.6x | 1.0x | 0.7x | 0.7x | 0.7x |
| Quick ratio | 1.0x | 0.5x | 0.4x | 0.6x | 0.5x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | — | — |
| Rule of 40 | −27.9% | 8.4% | 9.9% |
| Altman Z'' | −19.14 | −25.14 | −32.65 |
| Accruals ratio | −2.6% | −21.6% | −45.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | — | — |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 4 of 9 | — | — |
Compare
Put IM Cannabis side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| IM Cannabis | FY25 | 1.3% | −21.2% | 8.6% | −64.9% | — | — | |
| Nektar Therapeutics | FY25 | −43.9% | −253.7% | −377.8% | — | — | 2 | Compare |
| Agios Pharmaceuticals | FY25 | 48.0% | −873.9% | −698.3% | — | — | — | Compare |
| Ocular Therapeutix | FY25 | −18.5% | −519.8% | −417.5% | — | — | 4 | Compare |
| Aytu Biopharma | FY26 | −13.3% | −14.4% | 5.7% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 9 | 16 | 34 | 54 | 49 | 54 | 55 |
| Revenue growth | — | 75.1% | 114.3% | 59.6% | −10.2% | 10.7% | 1.3% |
| Gross profit | 4 | 10 | 6 | 9 | 10 | 8 | 10 |
| Research and development | 0 | 0 | — | — | — | — | — |
| Operating income | −10 | −8 | −23 | −31 | −13 | −10 | −12 |
| Net income | −7 | −29 | −18 | −189 | −10 | −11 | −11 |
| Diluted EPS (CAD) | −2.30 | −19.00 | −6.70 | −161.88 | −4.45 | −4.51 | −2.67 |
| Diluted shares (millions) | 3 | 4 | 6 | 8 | 13 | — | — |
| Cash flow | |||||||
| Cash from operations | −6 | −8 | −34 | −13 | −8 | −1 | 5 |
| Capital expenditure | 2 | 3 | 5 | 2 | 1 | 0 | 0 |
| Free cash flow | −8 | −11 | −39 | −14 | −9 | −1 | 5 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Acquisitions | 1 | 0 | 12 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 3 | 3 | 8 | 4 | 0 | 0 | 0 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 14 | 9 | 17 | — | 2 | 1 | 3 |
| Debt incl. finance leases | — | 0 | 13 | 10 | 13 | 16 | 16 |
| Total assets | 31 | 38 | 287 | 61 | 49 | 39 | 32 |
| Total liabilities | 5 | 26 | 82 | 37 | 35 | 36 | 35 |
| Shareholders' equity | 25 | 11 | 201 | 23 | 14 | 5 | −4 |
| Margins and ratios | |||||||
| Gross margin | 43.3% | 65.9% | 18.6% | 16.9% | 20.2% | 15.6% | 17.7% |
| Operating margin | −113.2% | −51.9% | −67.6% | −56.7% | −26.2% | −18.9% | −21.2% |
| Net margin | −80.4% | −180.6% | −52.2% | −347.6% | −19.5% | −19.6% | −20.7% |
| Free cash flow margin | −82.7% | −66.3% | −114.4% | −26.1% | −17.7% | −2.3% | 8.6% |
| Rule of 40 (growth + FCF margin) | — | 8.8% | −0.1% | 33.4% | −27.9% | 8.4% | 9.9% |
| Return on capital | — | — | −17.8% | — | — | −37.5% | −64.9% |
| Return on equity | — | −160.5% | −16.7% | −168.7% | −51.2% | −107.4% | — |
| Return on assets | — | −83.2% | −10.9% | −108.5% | −17.4% | −24.1% | −31.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — |